Ishami Mpuzamahanga

Ku ya 11 Kamena, Kelun-Biotech yatangaje ko ikigo cyayo cyakoze imiti ya TROP2 ADC sac-TMT (佳泰莱) cyigenga, hamwe na antibody ya PD-L1 monoclonal tagitanlimab (科泰莱), cyahawe isura ya Breakthrough Therapy (BTD) n'Ikigo gishinzwe gusuzuma imiti (CDE) cya Med National ...Soma byinshi»

Ku ya 29 Gicurasi, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) cyemeje icuruzwa rya Zanidatamab, ryatanzwe na BeiGene, mu kuvura abarwayi barwaye kanseri y’inkari idakira mu gace runaka cyangwa kanseri y’inkari itera ubwandu (BTC) babanje guhabwa ubuvuzi bw’umubiri kandi bagaragaza ko bafite HER2 nyinshi...Soma byinshi»

Ku ya 04 Kamena 2025, Akeso yatangaje ko Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) cyemeje umuti wa mbere w’isosiyete witwa cadonilimab, antibody ya PD-1/CTLA-4 bispecific, wo kuvura kanseri y’inkondo y’umura ihoraho, isubiramo, cyangwa ikwirakwira, hamwe na platinu...Soma byinshi»

Ku ya 29 Gicurasi, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) cyemeje umuti wa HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) kugira ngo ugurishwe. Ugaragazwa nk'uburyo bwo kuvura abarwayi bakuru bafite indwara idakira cyangwa isanzwe idakira mu gace runaka ...Soma byinshi»

Ku ya 21 Gicurasi 2025, InnoCare Pharma yatangaje ko Ikigo cy’Igihugu cy’Ubushinwa gishinzwe Ibikoresho by’Ubuvuzi (NMPA) cyemeye Minjuvi® (tafasitamab), umuti wa CD19 ukoreshwa mu buryo bwa muntu urwanya monoclonal antibody wahinduwe na Fc, hamwe na lenalidomide, hanyuma Minjuvi ikanakoreshwa mu buryo bwa monotherapy, kugira ngo ...Soma byinshi»

Ku ya 22 Gicurasi 2025, Allist Pharmaceuticals yatangaje ko umuti wayo mushya witwa Airuikai (Glecirasib Citrate Tablets), umuti ubuza KRAS-G12C, wemejwe ku mugaragaro ko utangira ku isoko n'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA). Ubwemere bwemerera Airuikai gukoreshwa mu kuvura...Soma byinshi»

Ku ya 22 Gicurasi 2025, Kelun Bio yatangaje ko ubusabe bushya bw'ikimenyetso cyayo cy'ubuso bwa antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, izwi kandi nka SKB264/MK - 2870) (®) bwemejwe n'Ikigo gishinzwe gusuzuma imiti (...Soma byinshi»

Mu rugamba rurambye rwo kurwanya kanseri, intwaro nshya zo kurwanya kanseri zikomeje kugaragara, zizanira abarwayi ibyiringiro bishya Mu ntambara ndende hagati y'abantu na kanseri, intwaro nshya zo kurwanya kanseri zirimo kugaragara imwe nyuma y'indi, zizanira abarwayi ibyiringiro bishya. Nk'igishya gishya ...Soma byinshi»

Mu 2021, umurwayi w’imyaka 67 wa kanseri y’agahinda yakoze igitangaza cy’ubuvuzi. Nyuma yo kubagwa, guhabwa imiti myinshi ya chimiotherapie, no kunanirwa kwa TIL therapy, igerageza rya TCR-T cell therapy yitabiriye ryatumye metastases y’ibihaha igabanukaho 72% mu mezi 6...Soma byinshi»

Ku ya 12 Gicurasi 2025, CARsgen yatangaje amakuru y'ibanze ku buvuzi bwa CT0596, CAR-T ikoreshwa mu buryo bwa allogeneic BCMA yakozwe hakoreshejwe urubuga rwa THANK-u Plus™. CT0596 ubu irimo gusuzumwa mu bushakashatsi bwa mbere ku buvuzi bwa myeloma nyinshi yasubiwemo/yasubiwemo (R/R MM) cyangwa yasubiwemo/yasubiwemo...Soma byinshi»

Ku ya 9 Gicurasi 2025, Hansoh Pharmaceutical yatangaje ko ikimenyetso gishya cya Ameile (ibinini bya almonertinib mesylate) cyemejwe ku isoko. Iki kimenyetso gishya ni icyo kuvura abarwayi bakuru barwaye kanseri y'ibihaha itari iy'uturemangingo duto (NSCLC) bafite ibibyimba bifite ubushobozi bwo gukura kw'inyuma y'uruhu...Soma byinshi»

Ku ya 1 Gicurasi 2025, Hansoh Pharmaceutical yatangaje ko umuti wa B7-H4-target antibody-drug conjugate (ADC) HS-20089 wikoreye itsinda wahawe uburenganzira bwo gushyirwa mu bwoko bwa Breakthrough-Therapy-Designed Medicine n'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) cyo mu Bushinwa, wi...Soma byinshi»